Description

Key Characteristics

• 40mg RETA + 20mg TIRZ per vial (60mg combined)
• Pairs a triple-receptor agonist with a dual-receptor agonist in one vial
• Single-vial format simplifies combined-protocol research

Primary Research Focus Areas

• Metabolic and body-composition models
• Appetite-regulation and glucose-metabolism research
• Comparative incretin-pathway studies

Preparation & Storage

• Reconstitute with bacteriostatic water; dissolve gently without shaking
• Store unreconstituted powder at -20°C
• Refrigerate reconstituted solution at 2–8°C; use within 30 days

Research Chemical: NOT FOR HUMAN CONSUMPTION. For laboratory research and in vitro use only. Not FDA approved.